VANCOUVER, British Columbia, August 7, 2026
AbCellera announced that it will release top-line results from the Phase 2 clinical trial of ABCL635 evaluating the investigational therapy in women with moderate-to-severe vasomotor symptoms (VMS) associated with menopause. The company expects to announce the data before the U.S. market opens on August 10, 2026, followed by an investor conference call and webcast. ABCL635 is being developed as a potential first-in-class, non-hormonal antibody treatment for menopausal symptoms including hot flashes.
Phase 2 Trial Evaluates ABCL635 in Menopausal VMS
The Phase 2 ABCL635 trial (NCT07118891) is a multicenter, randomized, double-blind, placebo-controlled study involving approximately 80 postmenopausal women. The trial is designed to evaluate the efficacy and safety of ABCL635, with particular focus on its ability to reduce the frequency and severity of moderate-to-severe vasomotor symptoms. The upcoming top-line readout is expected to provide an important clinical assessment of the program and help determine its potential for further development.
ABCL635 Targets the NK3R Pathway
ABCL635 is an investigational antibody drug targeting neurokinin 3 receptor (NK3R), a G protein-coupled receptor expressed on KNDy neurons in the hypothalamus. The NK3R pathway has been clinically validated as a target for treating menopausal VMS. AbCellera is developing ABCL635 as a non-hormonal approach, potentially offering an alternative for women who are unable or unwilling to use hormone-based treatments. The program entered clinical development in July 2025 and represents the first program from AbCellera’s GPCR and ion channel discovery platform to advance into its clinical pipeline
Advertisement
Top-Line Data Could Shape ABCL635 Development Path
The August 10 data release represents a significant upcoming milestone for AbCellera’s women’s health pipeline. Positive Phase 2 results could support further clinical development of ABCL635 and strengthen the company’s position in the emerging market for non-hormonal treatments for menopause-related VMS. AbCellera is also developing antibody-based medicines across endocrinology, women’s health, immunology, and oncology, with ABCL635 serving as an important clinical-stage program within its broader pipeline.
Source:AbCellera press release
